PRINCETON, NJ--(Marketwire - July 12, 2012) -
Agile Therapeutics announced today that Al Altomari, President and Chief Executive Officer, will be presenting at OneMedForum New York 2012. The biannual event, organized by OneMedPlace, takes place July 11-12, 2012 in New York.
Mr. Altomari will be speaking at 10:20 am ET on July 12. His presentation will provide an overview of the company's recent milestones, its pipeline of products, and its growth strategy, as well as information on its approach to commercialization. Agile is preparing for its first commercial launch and plans to enter the contraceptive market with AG200-15, a once-weekly, low-dose contraceptive patch. Agile recently filed the NDA for AG200-15, and anticipates a response in the first quarter of 2013.
"We are proud of our progress as a company and our lead product, a low-dose contraceptive patch that we feel will respond to the need for more convenient contraceptive choices," said Mr. Altomari. "I am looking forward to sharing this overview of Agile and our commercialization strategy at OneMedForum."
AG200-15 is a combination hormonal contraceptive patch, which in clinical studies has been shown to deliver a low dose of ethinyl estradiol, as well as a dose of levonorgestrel that is consistent with the efficacy and safety profile of low-dose oral contraceptives. The phase III trials for AG200-15 enrolled more than 2,000 women and formed the basis for the Company's application to the US Food and Drug Administration in 2012.
The AG200-15 patch is applied once weekly for three weeks, followed by a fourth, patch-free week. The patch may be applied to the abdomen, buttocks, or upper torso, is soft and flexible with a cloth-like, silky feel, and designed to provide excellent adhesion, comfort, and appearance.
About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company's lead product, AG200-15, is a once-weekly contraceptive patch that has been submitted to the FDA for approval. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.
OneMedPlace is a virtual community that connects emerging companies seeking capital, distribution, and visibility with investors and strategic partners looking for health and medical innovations to invest in, acquire, license, distribute, purchase or utilize.
Founded in 2008, OneMedForum events are held biannually in San Francisco in January and in New York in June/July. They are designed to create a communications platform for emerging companies to connect with strategic partners and investors.